Form 4: Corvus Pharmaceuticals Director Linda Grais Granted 15,000 Stock Options

Corvus Pharmaceuticals, Inc. Director Linda Grais was granted 15,000 stock options with an exercise price of $4.24, aligning her interests with shareholder value.

Summary

• Linda Grais, a Director of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each option has an exercise price of $4.24.
• The options are exercisable as of June 12, 2025, and expire on June 12, 2035.
• The underlying shares subject to the option will vest 100% on the earlier of the first anniversary of the grant date or the date of the 2026 Annual Meeting of the Issuer's stockholders, contingent on continuous service as a director.
• Following this transaction, Linda Grais beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholders, but it is a routine compensation matter and not indicative of significant new positive or negative company developments.

Positives

• The grant of stock options to Director Linda Grais aligns her financial interests with the long-term performance and shareholder value of Corvus Pharmaceuticals.
• The options have a 10-year expiration period (until June 12, 2035), providing a long-term incentive for the director.
• The vesting schedule encourages continuous service from the director, ensuring stability in governance.

Negatives

• No specific negatives are indicated in this Form 4 filing.

Risks

• The value of the stock options is dependent on the future stock price of Corvus Pharmaceuticals, Inc., which is subject to market fluctuations and company performance.
• If the stock price does not exceed the exercise price of $4.24, the options may expire worthless.

Future Outlook

The vesting schedule for the stock options indicates an expectation of continued service from Director Linda Grais until at least the first anniversary of the grant date or the 2026 Annual Meeting, whichever is earlier. This aligns the director's future efforts with the company's long-term success.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to attract and retain talent, and to align the interests of directors with those of shareholders. This type of compensation structure is particularly prevalent in growth-oriented sectors like biotech, where long-term value creation is a key focus.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation in the U.S. public company landscape, particularly within the biotech sector.
• While specific grant sizes and exercise prices vary by company size, stage, and individual director's role, a grant of 15,000 options is within a typical range for non-employee directors at a company like Corvus Pharmaceuticals.
• The 10-year expiration period is also a common industry standard for employee and director stock options.
• The vesting schedule, tied to continued service, is a standard mechanism to ensure retention and alignment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Linda Grais constitutes a related party transaction, as it involves compensation to a member of the company's board of directors. This is a standard and disclosed form of related party dealing.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.

Next Steps

• The stock options will vest on the earlier of June 12, 2026 (first anniversary of grant) or the date of the 2026 Annual Meeting of Stockholders, assuming continuous service.
• Following vesting, the director may choose to exercise the options at the stated exercise price of $4.24 per share, subject to the expiration date of June 12, 2035.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, SEC Form 4, stock option, director compensation, insider transaction, equity grant, corporate governance